home / stock / inzy / inzy message board
Subject | By | Source | When |
---|---|---|---|
znewcar1: $INZY 22% v2,6M c5.73 f43,720M H5.95 ML.2.51 RL4.51 gapNgo | znewcar1 | investorshangout | 04/01/2023 3:27:00 AM |
Loading | INFINITI | investorshub | 02/17/2023 1:19:27 PM |
Have a feeling this about to squeeze into | Jess070283 | investorshub | 02/16/2023 3:10:59 PM |
Great week so far. Gotta keep | tj9938 | investorshub | 01/06/2023 4:00:14 PM |
Quietest board out there | tj9938 | investorshub | 12/30/2022 6:58:51 PM |
Grabbed a starter here today | ErnieBilco | investorshub | 04/26/2022 3:00:20 PM |
INZ-701 is currently in a Phase 1/2 clinical | crudeoil24 | investorshub | 04/19/2022 1:41:02 AM |
Inozyme Pharma, Inc. is a clinical-stage rare disease | crudeoil24 | investorshub | 04/19/2022 1:36:53 AM |
Inozyme Pharma 13G Filing From Deep Track Capital | crudeoil24 | investorshub | 04/19/2022 1:33:01 AM |
I like the BioXc chart looks better. Thanks | tw0122 | investorshub | 04/14/2022 12:31:23 PM |
The offering is expected to close on or | crudeoil24 | investorshub | 04/14/2022 12:24:28 PM |
This analyst know about the offering? Inozyme Pharma, | tw0122 | investorshub | 04/14/2022 12:21:57 PM |
PT > 33.00 | crudeoil24 | investorshub | 04/14/2022 12:16:49 PM |
H.C. Wainwright analyst Edward White maintained a Buy | crudeoil24 | investorshub | 04/14/2022 12:16:25 PM |
News, Short Squeeze, Breakout and More Instantly...
Inozyme Pharma Inc. Company Name:
INZY Stock Symbol:
NASDAQ Market:
Shares of Tilray Brands, Inc. (NASDAQ: TLRY) fell sharply during Tuesday’s session after the company missed third-quarter estimates and said...
2024-04-09 08:00:07 ET Edward White from H.C. Wainwright issued a price target of $14.00 for INZY on 2024-04-09 06:36:00. The adjusted price target was set to $14.00. At the time of the announcement, INZY was trading at $5.87. INZY currently trades -24.97% versus its 52 ...
- Favorable safety and immunogenicity profile in ABCC6 Deficiency, with clinical improvements in vascular pathology, visual function and patient reported outcomes (PROs) - - Natural history study highlights stroke as common feature among patients with early-onset ABCC6 Deficiency - ...